Effects of alpha 1-adrenergic blockade on pulsatile luteinizing hormone, follicle-stimulating hormone, and prolactin secretion in polycystic ovary syndrome

J Clin Endocrinol Metab. 1987 Nov;65(5):841-6. doi: 10.1210/jcem-65-5-841.

Abstract

Central noradrenergic mechanisms may participate in the regulation of pulsatile gonadotropin secretion in women with the polycystic ovary syndrome (PCO). To examine this possibility we measured serum LH, FSH, and PRL concentrations at 10-min intervals and total testosterone and 17 beta-estradiol at 60-min intervals for 8 h basally and during the infusion of the alpha 1-adrenoceptor antagonist thymoxamine (10 micrograms/kg X min) in 10 young women with PCO. Mean and integrated serum LH concentrations as well as LH pulse frequency were not significantly altered (P = NS) during the thymoxamine infusion. However, we found an increase in LH pulse amplitude as both net (P less than 0.002) and percent (P less than 0.002) increment, as well as mean LH peak values (P less than 0.05) during alpha 1-adrenergic blockade. There were no significant changes in pulsatile FSH and PRL secretion or gonadal sex steroids during these experimental conditions. These data suggest that in PCO patients, 1) brain noradrenergic mechanisms do not play a stimulatory role in regulating the frequency of pulsatile LH secretion, 2) central noradrenergic activity inhibits LH pulse amplitude, and 3) PRL and FSH pulsatility are not altered by central noradrenergic blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic alpha-Antagonists / pharmacology*
  • Adult
  • Female
  • Follicle Stimulating Hormone / metabolism*
  • Humans
  • Luteinizing Hormone / metabolism*
  • Moxisylyte / pharmacology
  • Polycystic Ovary Syndrome / metabolism*
  • Prolactin / metabolism*
  • Pulsatile Flow

Substances

  • Adrenergic alpha-Antagonists
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Moxisylyte